Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Lung Cancer

Free Subscription 06.11.2023 1 Ann Thorac Surg 6 Anticancer Res 6 BMC Cancer 1 Br J Cancer 5 Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 2 Cancer Res 2 Chest 1 Clin Cancer Res 6 Clin Lung Cancer 2 Clin Nucl Med 1 Eur J Cancer 1 Eur J Cardiothorac Surg 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 6 J Cancer Res Clin Oncol 1 J Clin Invest 1 Lung Cancer 1 Nat Med

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Thorac Surg

1. MORKVED AL, Sogaard M, Skjoth F, Ording AG, et al
   Risk and timing of venous thromboembolism after surgery for lung cancer: a nationwide cohort study.
   Ann Thorac Surg. 2023 Oct 25:S0003-4975(23)01073.
   PubMed         Abstract available
   
   

   
   Anticancer Res

2. ITO S, Tsurumi K, Shindo N, Soma S, et al
   Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With EGFR-mutated Lung Adenocarcinoma.
   Anticancer Res. 2023;43:5031-5040.
   PubMed         Abstract available
   
   
3. SAKAI K, Kuramoto J, Takahashi T, Kawano Y, et al
   Impact of Locoregional Therapies for Brain Lesions on Survival in Patients With Non-small Cell Lung Cancer With Multiple Extrathoracic Metastases.
   Anticancer Res. 2023;43:5107-5114.
   PubMed         Abstract available
   
   
4. ITO A, Tarukawa T, Suzuki Y, Sakaguchi T, et al
   Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma.
   Anticancer Res. 2023;43:5197-5204.
   PubMed         Abstract available
   
   
5. YANG T, Si Q, Liu M, DU R, et al
   Novel Biomarker miRNA-625-3p Promotes Cell Proliferation and Metastasis of Lung Adenocarcinoma by Targeting KLF9.
   Anticancer Res. 2023;43:4923-4935.
   PubMed         Abstract available
   
   
6. MATSUDO K, Takenaka T, Hashinokuchi A, Nagano T, et al
   Impact of Chronic Obstructive Pulmonary Disease on the Long-term Prognosis of Patients Undergoing Lobectomy for Non-small-cell Lung Cancer: A Propensity Score-matched Analysis.
   Anticancer Res. 2023;43:5215-5222.
   PubMed         Abstract available
   
   
7. ISOYAMA-SHIRAKAWA Y, Yoshitake T, Ninomiya K, Asai K, et al
   Combination of Clinical Factors and Radiomics Can Predict Local Recurrence and Metastasis After Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer.
   Anticancer Res. 2023;43:5003-5013.
   PubMed         Abstract available
   
   

   
   BMC Cancer

8. ZHANG Y, Qu H, Tian Y, Na F, et al
   PB-LNet: a model for predicting pathological subtypes of pulmonary nodules on CT images.
   BMC Cancer. 2023;23:936.
   PubMed         Abstract available
   
   
9. WANG W, Wang S, Wang M, Ma Y, et al
   Effects of TRAF3 on the proliferation and migration of lung adenocarcinoma depend partly on pyroptosis.
   BMC Cancer. 2023;23:942.
   PubMed         Abstract available
   
   
10. CHEN Y, Gong L, Gu P, Hua Y, et al
    Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy.
    BMC Cancer. 2023;23:944.
    PubMed         Abstract available
    
    
11. GAO Y, Wang X, Zhao X, Zhu C, et al
    Multiphase CT radiomics nomogram for preoperatively predicting the WHO/ISUP nuclear grade of small (< 4 cm) clear cell renal cell carcinoma.
    BMC Cancer. 2023;23:953.
    PubMed         Abstract available
    
    
12. SONG Y, Lin S, Chen J, Dang J, et al
    First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1043.
    PubMed         Abstract available
    
    
13. WANG Y, Yu T, Chen J, Zhao R, et al
    Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity.
    BMC Cancer. 2023;23:1047.
    PubMed         Abstract available
    
    

    
    Br J Cancer

14. TANG M, Burgess JT, Fisher M, Boucher D, et al
    Targeting the COMMD4-H2B protein complex in lung cancer.
    Br J Cancer. 2023 Nov 1. doi: 10.1038/s41416-023-02476.
    PubMed         Abstract available
    
    

    
    Cancer

15. MAHAR AL, Biggs K, Hansford RL, Derksen S, et al
    Stage IV breast, colorectal, and lung cancer at diagnosis in adults living with intellectual or developmental disabilities: A population-based cross-sectional study.
    Cancer. 2023 Oct 30. doi: 10.1002/cncr.35068.
    PubMed         Abstract available
    
    
16. VAN VEGGEL BAMH, van der Wekken AJ, Paats MS, Hendriks LEL, et al
    A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
    Cancer. 2023 Oct 31. doi: 10.1002/cncr.35090.
    PubMed         Abstract available
    
    
17. HENDRICK RE, Smith RA
    Benefit-to-radiation-risk of low-dose computed tomography lung cancer screening.
    Cancer. 2023 Nov 1. doi: 10.1002/cncr.34855.
    PubMed         Abstract available
    
    
18. LANDY R, Cheung LC, Young CD, Chaturvedi AK, et al
    Absolute lung cancer risk increases among individuals with >15 quit-years: Analyses to inform the update of the American Cancer Society lung cancer screening guidelines.
    Cancer. 2023 Nov 1. doi: 10.1002/cncr.34758.
    PubMed         Abstract available
    
    
19. 
    Immunotherapy plus stereotactic radiation therapy improves event-free survival in early-stage non-small cell lung cancer.
    Cancer. 2023;129:3680.
    PubMed        
    
    

    
    Cancer Epidemiol Biomarkers Prev

20. YANG Z, He H, He G, Zeng C, et al
    Investigating Causal Effects of Hematological Traits on Lung Cancer: A Mendelian Randomization Study.
    Cancer Epidemiol Biomarkers Prev. 2023 Nov 1. doi: 10.1158/1055-9965.EPI-23-0725
    PubMed         Abstract available
    
    

    
    Cancer Lett

21. LI B, Chen Q, Feng Y, Wei T, et al
    Glucose restriction induces AMPK-SIRT1-mediated circadian clock gene Per expression and delays NSCLC progression.
    Cancer Lett. 2023;576:216424.
    PubMed         Abstract available
    
    

    
    Cancer Res

22. COTTON JL, Estrada Diez J, Sagar V, Chen J, et al
    Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance.
    Cancer Res. 2023;83:3611-3623.
    PubMed         Abstract available
    
    
23. WEBER MC, Izzo LT, Oliver TG
    Epigenetic Regulators Open the Door to SCLC Plasticity.
    Cancer Res. 2023;83:3495-3497.
    PubMed         Abstract available
    
    

    
    Chest

24. WELCH AC, London SM, Wilshire CL, Gilbert CR, et al
    Access to Lung Cancer Screening Among American Indians and Alaska Natives: A Qualitative Study.
    Chest. 2023 Oct 26:S0012-3692(23)05670-2. doi: 10.1016/j.chest.2023.
    PubMed         Abstract available
    
    
25. CREAMER AW, Horst C, Dickson JL, Tisi S, et al
    Full title: Stage at diagnosis following delay to interval scans for indeterminate nodules in lung cancer screening: An observational study examining the outcomes of CHEST expert panel recommendations.
    Chest. 2023 Oct 30:S0012-3692(23)05678-7. doi: 10.1016/j.chest.2023.
    PubMed        
    
    

    
    Clin Cancer Res

26. HERBST RS, Blanke CD, Sigal EV
    Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of Public-Private Partnerships.
    Clin Cancer Res. 2023 Oct 30. doi: 10.1158/1078-0432.CCR-23-2690.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

27. ADACHI H, Morohoshi T, Shintani Y, Okami J, et al
    Benefit of Adjuvant Chemotherapy for Patients Older Than 75 Years With Completely Resected p-Stage II-IIIA Non-Small-Cell Lung Cancer: A Retrospective Cohort Study Using Japanese Nationwide Real-World Data.
    Clin Lung Cancer. 2023 Oct 12:S1525-7304(23)00192.
    PubMed         Abstract available
    
    
28. WOLF J, Souquet PJ, Goto K, Cortot A, et al
    Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
    Clin Lung Cancer. 2023;24:641-650.
    PubMed         Abstract available
    
    
29. FRICKE J, Wang J, Gallego N, Mambetsariev I, et al
    Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.
    Clin Lung Cancer. 2023;24:666-671.
    PubMed        
    
    
30. MALLAEV M, Chirindel AF, Lardinois D, Tamm M, et al
    3D-Quantitated Single Photon Emission Computed Tomography/Computed Tomography: Impact on intended Management Compared to Lung Perfusion Scan in Marginal Candidates for Pulmonary Resection.
    Clin Lung Cancer. 2023;24:621-630.
    PubMed         Abstract available
    
    
31. LEE KH, Chung JH, Cho S, Lee JS, et al
    Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
    Clin Lung Cancer. 2023;24:e291-e299.
    PubMed         Abstract available
    
    
32. ASAO T, Shukuya T, Mimori T, Goto Y, et al
    Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
    Clin Lung Cancer. 2023;24:e247-e253.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

33. LI H, Li C, Tian Y, Wen B, et al
    Increased 68 Ga-FAPI Uptake in Pulmonary Sclerosing Pneumocytoma.
    Clin Nucl Med. 2023;48:989-990.
    PubMed         Abstract available
    
    
34. UMEHANA M, Hosono M, Hijikata Y, Takahashi M, et al
    Pembrolizumab-Associated Pneumonitis Resembling Lymphangitic Carcinomatosis in a Melanoma Patient.
    Clin Nucl Med. 2023;48:e529-e531.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

35. YAMADA T, Goto Y, Tanaka H, Kimura H, et al
    A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
    Eur J Cancer. 2023;195:113373.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

36. KAPLAN T, Keskin UE, Kapan OF, Han S, et al
    Editorial comment correlation between postoperative cognitive dysfunction and the extent of lung resection in lung cancer patients.
    Eur J Cardiothorac Surg. 2023 Oct 27:ezad356. doi: 10.1093.
    PubMed        
    
    

    
    Int J Oncol

37. SHIE WY, Chu PH, Kuo MY, Chen HW, et al
    Acidosis promotes the metastatic colonization of lung cancer via remodeling of the extracellular matrix and vasculogenic mimicry.
    Int J Oncol. 2023;63:136.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

38. GAUDREAULT M, Bucknell N, Woon B, Kron T, et al
    Dose-response relationship between radiotherapy and loss of lung perfusion comparing positron emission tomography and dual-energy computed tomography in non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2023 Oct 30:S0360-3016(23)08047.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

39. GAO R, Gao Y, Zhang J, Zhu C, et al
    A nomogram for predicting invasiveness of lung adenocarcinoma manifesting as pure ground-glass nodules: incorporating subjective CT signs and histogram parameters based on artificial intelligence.
    J Cancer Res Clin Oncol. 2023;149:15323-15333.
    PubMed         Abstract available
    
    
40. CHANG Y, Xing H, Shang Y, Liu Y, et al
    Preoperative predicting invasiveness of lung adenocarcinoma manifesting as ground-glass nodules based on multimodal images of dual-layer spectral detector CT radiomics models.
    J Cancer Res Clin Oncol. 2023;149:15425-15438.
    PubMed         Abstract available
    
    
41. MILJANIC M, Nwachukwu C, Rahimi A
    Definitive ablative stereotactic partial breast irradiation in early stage inoperable breast cancer.
    J Cancer Res Clin Oncol. 2023;149:15553-15559.
    PubMed         Abstract available
    
    
42. ZHANG G, Guan H, Ning YL, Yao K, et al
    Osimertinib resistance prognostic gene signature: STRIP2 is associated with immune infiltration and tumor progression in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:15573-15588.
    PubMed         Abstract available
    
    
43. ZHOU J, Fang P, Liang Z, Li X, et al
    Causal relationship between lung diseases and risk of esophageal cancer: insights from Mendelian randomization.
    J Cancer Res Clin Oncol. 2023;149:15679-15686.
    PubMed         Abstract available
    
    
44. WANG Y, Yan C, Zhang C, Yu E, et al
    The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib.
    J Cancer Res Clin Oncol. 2023;149:16069-16073.
    PubMed         Abstract available
    
    

    
    J Clin Invest

45. MAKINEN N, Meyerson M
    Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
    J Clin Invest. 2023;133:e174171.
    PubMed         Abstract available
    
    

    
    Lung Cancer

46. MANGLAVITI S, Bini M, Apollonio G, Zecca E, et al
    High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
    Lung Cancer. 2023;186:107417.
    PubMed         Abstract available
    
    

    
    Nat Med

47. DEUTSCH JS, Cimino-Mathews A, Thompson E, Provencio M, et al
    Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
    Nat Med. 2023 Oct 30. doi: 10.1038/s41591-023-02660.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.